NCT02000596View on ClinicalTrials.gov

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

January 31, 2016

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Trastuzumab plus Pertuzumab

DRUG

Hormonal Therapy with Anastrozole and Fulvestrant

Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days

DRUG

Chemotherapy with Eribulin

Trial Locations (1)

21201

University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Maryland, Baltimore

OTHER